Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Bas, Sylvette ^a   James, Richard W ^a   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; BACTERIAL PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 8; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROPHAGE INFECTIVITY POTENTIATOR PROTEIN; OUTER SURFACE PROTEIN A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CD14 ANTIGEN; OUTER MEMBRANE PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; BORRELIA BURGDORFERI; CELL DIFFERENTIATION; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EMBRYO; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE ACTIVATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; BIOSYNTHESIS; CHLAMYDIA TRACHOMATIS; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; ISOLATION AND PURIFICATION; METABOLISM; SERUM; TUMOR CELL LINE;

ANTIGENS, CD14; BACTERIAL OUTER MEMBRANE PROTEINS; BORRELIA BURGDORFERI; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHLAMYDIA TRACHOMATIS; HUMANS; IMMUNOMODULATION; INTERLEUKIN-8; LIPOPROTEINS; MACROPHAGE ACTIVATION; SERUM; TETRADECANOYLPHORBOL ACETATE; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956565101     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-46     Document Type: Article

References (55)

1. Hasebe A, HH M, Washburn LR, Chan FV, Pennock ND, Taylor ML, Cole BC. Inflammatory lipoproteins purified from a toxigenic and arthritogenic strain of Mycoplasma arthritidis are dependent on Toll-like receptor 2 and CD14. Infect Immun 2007, 75:1820-6. 10.1128/IAI.00516-06, 1865712, 17283106.
2. Bas S, Neff L, Vuillet M, Spenato U, Seya T, Matsumoto M, Gabay C. The Proinflammatory Cytokine Response to Chlamydia trachomatis Elementary Bodies in Human Macrophages Is Partly Mediated by a Lipoprotein, the Macrophage Infectivity Potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol 2008, 180:1158-68.
3. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, Han SH, Lee H, Paik SG, Lee JO. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009, 31:873-84. 10.1016/j.immuni.2009.09.018, 19931471.
4. Sankaran K, Wu HC. Lipid modification of bacterial prolipoprotein. Transfer of diacylglyceryl moiety from phosphatidylglycerol. J Biol Chem 1994, 269:19701-6.
5. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-82. 10.1016/j.cell.2007.09.008, 17889651.
6. Neff L, Daher S, Muzzin P, Spenato U, Gulacar F, Gabay C, Bas S. Molecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein. J Bacteriol 2007, 189:4739-48. 10.1128/JB.01889-06, 1913453, 17449608.
7. Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005, 11:97-103.
8. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007, 33:25-35. 10.1007/s00134-006-0433-x, 17093984.
9. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 1999, 40:245-52.
10. Haylett AK, Moore JV. Comparative analysis of foetal calf and human low density lipoprotein: relevance for pharmacodynamics of photosensitizers. J Photochem Photobiol B 2002, 66:171-8. 10.1016/S1011-1344(02)00241-5, 11960726.
11. Forte TM, Bell-Quint JJ, Cheng F. Lipoproteins of fetal and newborn calves and adult steer: a study of developmental changes. Lipids 1981, 16:240-5. 10.1007/BF02535023, 7242276.
12. Thompson PA, Kitchens RL. Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J Immunol 2006, 177:4880-7.
13. Kane JP, Sata T, Hamilton RL, Havel RJ. Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest 1975, 56:1622-34. 10.1172/JCI108245, 333142, 172534.
14. Massamiri T, Tobias PS, Curtiss LK. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. J Lipid Res 1997, 38:516-25.
15. Vreugdenhil AC, Snoek AM, van 't Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001, 107:225-34. 10.1172/JCI10832, 199173, 11160139.
16. Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van 't Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003, 170:1399-405.
17. Heumann D, Bas S, Gallay P, Le Roy D, Barras C, Mensi N, Glauser MP, Vischer T. Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein. J Rheumatol 1995, 22:1224-9.
18. Segrest JP, Jones MK, Mishra VK, Pierotti V, Young SH, Boren J, Innerarity TL, Dashti N. Apolipoprotein B-100: conservation of lipid-associating amphipathic secondary structural motifs in nine species of vertebrates. J Lipid Res 1998, 39:85-102.
19. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979, 64:1516-24. 10.1172/JCI109610, 371301, 227936.
20. Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001, 69:2821-8. 10.1128/IAI.69.5.2821-2828.2001, 98230, 11292694.
21. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990, 86:696-702. 10.1172/JCI114765, 296783, 2394827.
22. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993, 61:5140-6. 281294, 8225591.
23. Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992, 60:596-601. 257670, 1730494.
24. Yan YJ, Li Y, Lou B, Wu MP. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 2006, 79:210-5. 10.1016/j.lfs.2006.02.011, 16574162.
25. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest 1997, 99:2438-45. 10.1172/JCI119427, 508084, 9153287.
26. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ, Vogel T, Panet A, Van Berkel TJ, Kuiper J. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001, 276:8820-4. 10.1074/jbc.M009915200, 11136731.
27. Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun 2003, 71:3280-4. 10.1128/IAI.71.6.3280-3284.2003, 155762, 12761109.
28. Bhakdi S, Tranum-Jensen J, Utermann G, Fussle R. Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J Biol Chem 1983, 258:5899-904.
29. Miyakawa H, Honma K, Qi M, Kuramitsu HK. Interaction of Porphyromonas gingivalis with low-density lipoproteins: implications for a role for periodontitis in atherosclerosis. J Periodontal Res 2004, 39:1-9. 10.1111/j.1600-0765.2004.00697.x, 14687221.
30. Park KH, Yang HB, Kim HG, Lee YR, Hur H, Kim JS, Koo BS, Han MK, Kim JH, Jeong YJ, et al. Low density lipoprotein inactivates Vibrio vulnificus cytolysin through the oligomerization of toxin monomer. Med Microbiol Immunol 2005, 194:137-41. 10.1007/s00430-004-0227-0, 15834753.
31. Han R, Caswell CC, Lukomska E, Keene DR, Pawlowski M, Bujnicki JM, Kim JK, Lukomski S. Binding of the low-density lipoprotein by streptococcal collagen-like protein Scl1 of Streptococcus pyogenes. Mol Microbiol 2006, 61:351-67. 10.1111/j.1365-2958.2006.05237.x, 16856940.
32. Hasebe A, Pennock ND, Mu HH, Chan FV, Taylor ML, Cole BC. A microbial TLR2 agonist imparts macrophage-activating ability to apolipoprotein A-1. J Immunol 2006, 177:4826-32.
33. Makoveichuk E, Cherepanov P, Lundberg S, Forsberg A, Olivecrona G. pH6 antigen of Yersinia pestis interacts with plasma lipoproteins and cell membranes. J Lipid Res 2003, 44:320-30. 10.1194/jlr.M200182-JLR200, 12576514.
34. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 2006, 103:2126-31. 10.1073/pnas.0506877103, 1413691, 16452169.
35. Narayanaswami V, Kiss RS, Weers PM. The helix bundle: a reversible lipid binding motif. Comp Biochem Physiol A Mol Integr Physiol 155:123-33. 10.1016/j.cbpa.2009.09.009, 19770066.
36. Sellati TJ, Bouis DA, Kitchens RL, Darveau RP, Pugin J, Ulevitch RJ, Gangloff SC, Goyert SM, Norgard MV, Radolf JD. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. J Immunol 1998, 160:5455-64.
37. Giambartolomei GH, Dennis VA, Lasater BL, Philipp MT. Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14. Infect Immun 1999, 67:140-7. 96289, 9864208.
38. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999, 285:736-9. 10.1126/science.285.5428.736, 10426996.
39. Hsu SH, Lo YY, Tung JY, Ko YC, Sun YJ, Hung CC, Yang CW, Tseng FG, Fu CC, Pan RL. Leptospiral outer membrane lipoprotein LipL32 binding on toll-like receptor 2 of renal cells as determined with an atomic force microscope. Biochemistry 49:5408-17. 10.1021/bi100058w, 20513152.
40. Shin DM, Yang CS, Lee JY, Lee SJ, Choi HH, Lee HM, Yuk JM, Harding CV, Jo EK. Mycobacterium tuberculosis lipoprotein-induced association of TLR2 with protein kinase C zeta in lipid rafts contributes to reactive oxygen species-dependent inflammatory signalling in macrophages. Cell Microbiol 2008, 10:1893-905. 10.1111/j.1462-5822.2008.01179.x, 2785852, 18503635.
41. Salazar JC, Pope CD, Moore MW, Pope J, Kiely TG, Radolf JD. Lipoprotein-dependent and -independent immune responses to spirochetal infection. Clin Diagn Lab Immunol 2005, 12:949-58. 1182186, 16085913.
42. Machata S, Tchatalbachev S, Mohamed W, Jansch L, Hain T, Chakraborty T. Lipoproteins of Listeria monocytogenes are critical for virulence and TLR2-mediated immune activation. J Immunol 2008, 181:2028-35.
43. Pugsley AP, Kornacker MG, Ryter A. Analysis of the subcellular location of pullulanase produced by Escherichia coli carrying the pulA gene from Klebsiella pneumoniae strain UNF5023. Mol Microbiol 1990, 4:59-72. 10.1111/j.1365-2958.1990.tb02015.x, 2181241.
44. Bouvier J, Pugsley AP, Stragier P. A gene for a new lipoprotein in the dapA-purC interval of the Escherichia coli chromosome. J Bacteriol 1991, 173:5523-31. 208266, 1885529.
45. Zhang H, Niesel DW, Peterson JW, Klimpel GR. Lipoprotein release by bacteria: potential factor in bacterial pathogenesis. Infect Immun 1998, 66:5196-201. 108648, 9784522.
46. Cao P, McClain MS, Forsyth MH, Cover TL. Extracellular release of antigenic proteins by Helicobacter pylori. Infect Immun 1998, 66:2984-6. 108299, 9596777.
47. Hellman J, Roberts JD, Tehan MM, Allaire JE, Warren HS. Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in gram-negative sepsis and causes inflammation and death in mice. J Biol Chem 2002, 277:14274-80. 10.1074/jbc.M109696200, 11830585.
48. Dasari S, Pereira L, Reddy AP, Michaels JE, Lu X, Jacob T, Thomas A, Rodland M, Roberts CT, Gravett MG, et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res 2007, 6:1258-68. 10.1021/pr0605419, 17373839.
49. Tang LJ, De Seta F, Odreman F, Venge P, Piva C, Guaschino S, Garcia RC. Proteomic analysis of human cervical-vaginal fluids. J Proteome Res 2007, 6:2874-83. 10.1021/pr0700899, 17539673.
50. Kawai S, Nakajima T, Hokari S, Komoda T, Kawai K. Apolipoprotein A-I concentration in tears in diabetic retinopathy. Ann Clin Biochem 2002, 39:56-61. 10.1258/0004563021901748, 11853190.
51. Kitchens RL, Thompson PA, O'Keefe GE, Munford RS. Plasma constituents regulate LPS binding to, and release from, the monocyte cell surface. J Endotoxin Res 2000, 6:477-82.
52. Bas S, Muzzin P, Ninet B, Bornand JE, Scieux C, Vischer TL. Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens. J Clin Microbiol 2001, 39:1368-77. 10.1128/JCM.39.4.1368-1377.2001, 87941, 11283058.
53. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34:1345-53. 10.1172/JCI103182, 438705, 13252080.
54. James RW, Pometta D. Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis 1990, 83:35-45. 10.1016/0021-9150(90)90128-6, 2117929.
55. Huang XQ, Hardison RC, Miller W. A space-efficient algorithm for local similarities. Comput Appl Biosci 1990, 6:373-81.